Hostname: page-component-745bb68f8f-mzp66 Total loading time: 0 Render date: 2025-02-06T08:49:12.809Z Has data issue: false hasContentIssue false
  • English
  • Français

The efficacy and safety of comfrey

Published online by Cambridge University Press:  02 January 2007

Felix Stickel  and
Helmut K Seitz
Felix Stickel*
Affiliation:
Department of Medicine I, Division of Gastroenterology and Hepatology, University of Erlangen-Nuernberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
Helmut K Seitz
Affiliation:
Laboratory of Alcohol Research, Salem Medical Center, University of Heidelberg, Germany
*
*Corresponding author: Email felix.stickelamed1.med.uni-erlangen.de
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Herbal medication has gathered increasing recognition in recent years with regard to both treatment options and health hazards. Pyrrolizidine alkaloids have been associated with substantial toxicity after their ingestion as tea and in the setting of contaminated cereals have led to endemic outbreaks in Jamaica, India and Afghanistan. In Western Europe, comfrey has been applied for inflammatory disorders such as arthritis, thrombophlebitis and gout and as a treatment for diarrhoea. Only recently was the use of comfrey leaves recognized as a substantial health hazard with hepatic toxicity in humans and carcinogenic potential in rodents. These effects are most likely due to various hepatotoxic pyrrolizidine alkaloids such as lasiocarpine and symphytine, and their related N-oxides. The mechanisms by which toxicity and mutagenicity are conveyed are still not fully understood, but seem to be mediated through a toxic mechanism related to the biotransformation of alkaloids by hepatic microsomal enzymes. This produces highly reactive pyrroles which act as powerful alkylating agents. The main liver injury caused by comfrey (Symphytum officinale) is veno-occlusive disease, a non-thrombotic obliteration of small hepatic veins leading to cirrhosis and eventually liver failure. Patients may present with either acute or chronic clinical signs with portal hypertension, hepatomegaly and abdominal pain as the main features.

Therapeutic approaches include avoiding intake and, if hepatic failure is imminent, liver transplantation. In view of the known serious hazards and the ban on distributing comfrey in Germany and Canada, it is difficult to understand why comfrey is still freely available in the United States.

Keywords

ComfreyVeno-occlusive diseaseHerbal medicinePyrrolizidine alkaloids
Type
Research Article
Information
Public Health Nutrition , Volume 3 , Supplement 4a , December 2000 , pp. 501 - 508
Copyright
Copyright © CABI Publishing 2000

References

1: Brown, JS, Marcy, SA. The use of botanicals for health purposes by members of a prepaid health plan. Res. Nurs. Health 1991; 14: 339–50.CrossRefGoogle ScholarPubMed
2: Moore, J, Phipps, K, Marcer, D, Lewith, G.Why do people seek treatment by alternative medicine?. Br. Med. J. 1985; 290: 28–9.CrossRefGoogle ScholarPubMed
3: Winslow, LC, Kroll, DJ. Herbs as medicine. Arch. Intern. Med. 1998; 158: 2192–9.CrossRefGoogle Scholar
4: Schuppan, D, Jia, JD, Brinkhaus, B, Hahn, EG. Herbal products for liver disease: a therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099–104.Google Scholar
5: Trevelyan, J.Herbal medicine. Nurs. Times 1993; 89: 36–8.Google ScholarPubMed
6: Schiano, T. Liver injury from herbs and other botanicals. In: Gitlin, N, ed. Clinics in Liver Disease, vol. 2. Chicago: W.B. Saunders, 1998: 607–30.Google Scholar
7: Smith, LW, Culvenor, CCJ. Plant sources of hepatotoxic pyrrolizidine alkaloids. J. Nat. Prod. 1981; 44: 129–52.CrossRefGoogle ScholarPubMed
8: Wilmot, FC, Robertson, GW. Senecio disease or cirrhosis of the liver due to senecio poisoning. Lancet 1920; II, 828–828.Google Scholar
9: Selzer, G, Parker, RGF. Senecio poisoning exhibiting as Chiari's syndrome. Am. J. Pathol. 1951; 27: 885–907.Google ScholarPubMed
10: Bras, G, Jeliffe, DB, Stuart, KL. Veno-occlusive disease of the liver with non-portal type of cirrhosis, occurring in Jamaica. AMA Arch. Pathol. 1954; 57: 285–300.Google Scholar
11: Mohabat, O, Srivastava, RN, Younos, MS, Gholam Gsediq, GG, Merzad, AA, Aram, GN. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. Lancet 1976; 2: 269–71.Google Scholar
12: Tandon, BN, Tandon, RK, Tandon, HD, Narndranathan, M.An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2: 271–2.CrossRefGoogle ScholarPubMed
13: Stillman, AS, Huxtable, RJ, Consroe, P, Kohnen, P, Smith, S.Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 1977; 73: 349–52.Google Scholar
14: Fox, DW, Hart, MC, Bergeson, PS, Jarrett, PB, Stillman, AE, Huxtable, RJ. Pyrrolizidine (Senecio) intoxication mimicking Reye's syndrome. J. Paediatr. 1978; 93: 980–2.CrossRefGoogle Scholar
15: Ridker, PM, Ohkuma, S, McDermott, WV, Trey, C, Huxtable, RJ. Hepatic venoocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88: 1050–4.CrossRefGoogle Scholar
16: Weston, CFM, Cooper, BT, Davies, JD. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br. Med. J. 1987; 295: 183.Google Scholar
17: Bach, N, Thung, SN, Schaffner, F.Comfrey herb tea-induced hepatic veno-occlusive disease. Am. J. Med. 1989; 87: 97–9.CrossRefGoogle ScholarPubMed
18: Prakash, AS, Pereira, TN, Reilly, PE, Seawright, AA. Pyrrolizidine alkaloids in human diet. Mutat. Res. 1999; 15 (443): 53–67.Google Scholar
19: Comfrey In: The Lawrence Review of Natural Products Monograph System. Pharmaceutical Information Associates, 1987;.Google Scholar
20: Roitman, JN. Comfrey and liver damage. Lancet 1981; 1: 944.CrossRefGoogle ScholarPubMed
21: Huxtable, RJ, Lüthy, J, Zweifel, U.Toxicity of comfrey-pepsin preparations. N. Engl. J. Med. 1986; 315: 1095.Google Scholar
22: Ahmad, VU, Noorwala, M, Mohammad, FV, Sener, B.A new triterpene glycoside from the roots of Symphytum officinale. J. Nat. Prod. 1993; 56: 329–34.Google Scholar
23: Ahmad, VU, Noorwala, M, Mohammad, FV, Sener, B, Gilani, AH, Aftab, K.Symphytoxide A, a triterpenoid saponin from the roots of Symphytum officinale. Phytochemistry 1993; 32: 1003–6.Google Scholar
24: Stegelmeier, BL, Edgar, JA, Colegate, SM, Gardner, DR, Schoch, TK, Coulombe, RA et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J. Nat. Toxins 1999; 8: 95–116.Google ScholarPubMed
25: Betz, JM, Eppley, RM, Taylor, WC, Andrzejewski, D.Determination of pyrrolizidine alkaloids in commercial comfrey products (Symphytum sp.). J. Pharm. Sci. 1994; 83: 649–53.CrossRefGoogle ScholarPubMed
26: Mattocks, AR. Toxic pyrrolizidine alkaloids in comfrey. Lancet 1980; 2: 1136.Google Scholar
27: Nebert, DW, Nelson, DR, Coon, MJ, Estabrook, RW, Feyereisen, R, Fuji-Kuriyama, Y et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10: 1–14.Google Scholar
28: Huxtable, RJ. New aspects of the toxicology and pharmacology of pyrrolizidine alkaloids. Gen. Pharmacol. 1979; 10: 159–67.CrossRefGoogle ScholarPubMed
29: Couet, CE, Hopley, J, Hanley, AB. Metabolic activation of pyrrolizidine alkaloids by human, rat and avocado microsomes. Toxicon 1996; 34: 1058–61.CrossRefGoogle ScholarPubMed
30: Mattocks, AR. Chemistry and Toxicology of Pyrrolizidine Alkaloids, London: Academic Press, 1986: 1.Google Scholar
31: McLean, EK. Senecio and other plants as liver poisons. Isr. J. Med. Sci. 1974; 10: 436–40.Google Scholar
32: Mattocks, AR. Spectrophotometric determination of pyrrolizidine alkaloids – some improvements. Anal. Chem. 1968; 40: 1749–50.Google Scholar
33: Brauchli, J, Lüthy, J, Zweifel, U, Schlatter, C.Pyrrolizidine alkaloids from Symphytum officinale L. and their percutaneous absorbtion in rats. Experientia 1982; 38: 1085–7.CrossRefGoogle Scholar
34: Couet, CE, Crews, C, Hanley, AB. Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (Symphytum officinale). Nat. Toxins 1996; 4: 163–7.Google Scholar
35: Lin, G, Zhou, KY, Zhao, XG, Wang, ZT, But, PP. Determination of hepatotoxic pyrrolizidine alkaloids by on-line high performance liquid chromatography mass spectrometry with an electrospray interphase. Rapid Commun. Mass Spectrom. 1998; 12: 1445–56.Google Scholar
36: Roulet, M, Laurini, R, Rivier, L, Calame, A.Hepatic veno-occlusive disease in a newborn infant of a woman drinking herbal tea. J. Pediatr. 1988; 2: 481–500.Google Scholar
37: Sperl, W, Stuppner, H, Gassner, J, Judmaier, W, Dietze, O, Vogel, W.Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea. Eur. J. Pediatr. 1995; 154: 112–16.CrossRefGoogle Scholar
38: Essell, JH, Thomson, JM, Harman, GS, Halvorson, RD, Snyder, MJ, Johnson, RA et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for Graft-Versus-Host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784–8.CrossRefGoogle ScholarPubMed
39: Fried, MW, Connaghan, DG, Sharma, S, Martin, LG, Devine, S, Holland, K et al. Tranjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24: 588–91.Google Scholar
40: Alpert, LI. Veno-occlusive disease of the liver associated with oral contraceptives: case report and review of the literature. Hum. Pathol. 1976; 7: 709–-18.CrossRefGoogle Scholar
41: Pappas, SC, Malone, DG, Rabin, L, Hoofnagel, YH, Jones, EA. Hepatic veno-occlusive disease in a patient with systemic lupus erythematosus. Arthritis Rheum. 1984; 27: 104–8.Google Scholar
42: Goodman, ZD, Ishak, KG. Occlusive venous lesions in alcoholic liver disease. Gastroenterology 1982; 83: 786–96.CrossRefGoogle ScholarPubMed
43: Rollins, BJ. Hepatic veno-occlusive disease. Am. J. Med. 1990; 81: 297–306.CrossRefGoogle Scholar
44: Shulman, HM, Fisher, LB, Schoch, HG, Henne, KW, McDonald, GB. Venooclusive disease of the liver after marrow transplantation: histological correlates of clinical sign and symptoms. Hepatology 1994; 19: 1171–80.Google Scholar
45: Sherlock, S.Noncirrhotic extrahepatic and intrahepatic portal hypertension. Semin. Liver Dis. 1982; 2: 202–10.CrossRefGoogle ScholarPubMed
46: Yeong, ML, Wakefield, St J, Ford, HC. Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. Int. J. Exp. Pathol. 1993; 74: 211–17.Google Scholar
47: Brooks, SEH, Miller, CG, McKenzie, K, Audretsch, JJ, Bras, G.Acute veno-occlusive disease of the liver. Arch. Pathol. 1970; 89: 507–20.Google Scholar
48: Franke, H.Substructural alterations of liver parenchymal cells induced by xenobiotics. Exp. Pathol. 1990; 39: 139–55.Google Scholar
49: Jewell, S, Bellomo, G, Thor, H, Orrenius, S.Bleb formation in hepatocytes during drug metabolism is caused by disturbances in thiol and calcium ion homeostasis. Science 1982; 217: 1257–8.Google Scholar
50: Miskelly, FG, Goodyer, LI. Hepatic and pulmonary complications of herbal medicines. Postgrad. Med. J. 1992; 68: 935–6.CrossRefGoogle ScholarPubMed
51: Shubat, PJ, Banner, W, Huxtable, RJ. Pulmonary vascular response induced by the pyrrolizidine alkaloid monocrotaline in rats. Toxicon 1987; 25: 995–1002.CrossRefGoogle ScholarPubMed
52: Guzowski, DE, Solgado, ED. Changes in main pulmonary artery of rats with monocrotaline induced pulmonary hypertension. Arch. Pathol. Lab. Med. 1987; 111: 741–5.Google Scholar
53: Hirono, I, Haga, M, Fujii, M, Mori, H.Induction of hepatic tumors in rats by senkirkine and symphytine. J. Natl. Cancer Inst. 1979; 63: 469–72.Google Scholar
54: Petry, TW, Bowden, GT, Huxtable, RJ, Sipes, IG. Characterization of hepatic DNA damage induced in rats by the pyrrolizidine alkaloid monocrotaline. Cancer Res. 1984; 44: 1505–9.Google ScholarPubMed
55: Behninger, C, Abel, G, Roder, E, Neuberger, V, Goggelmann, W.Studies on the effect of an alkaloid extract of Symphytum officinale on human lymphocyte cultures. Planta Med. 1989; 55: 518–22.Google Scholar
56: Olinescu, A, Manda, G, Neagu, M, Hristescu, M, Dasanu, C.Action of some proteic and carbohydrate components of Symphytum officinale upon normal and neoplastic cells. Roum. Arch. Microbiol. Immunol. 1993; 52: 73–80.Google ScholarPubMed
57: Culvenor, CC. Estimated intakes of pyrrolizidine alkaloids by humans. A comparison with dose rates causing tumors in rats. J. Toxicol. Environ. Health 1983; 11: 625–35.Google Scholar
58: Zimmermann, HJ, Lewis, JH. Chemical and toxin-induced liver disease. Gastroenterol. Clin. N. Am. 1995; 24: 739.CrossRefGoogle Scholar
59: Larrey, D.Hepatotoxicity of herbal remedies. J. Hepatol. 1997; 26: 47–54.Google Scholar
60: Eltumi, M, Trivedi, P, Hobbs, JR, Portman, B, Cheeseman, P, Downie, C et al. Monitoring of venoocclusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993; 342: 518–21.CrossRefGoogle ScholarPubMed
61: Lassau, N, Leclére, J, Auperin, A, Bourhis, JH, Hartman, O, Valteau-Couanet, D et al. Hepatic veno-occlusive disease after myoablative treatment and bone marrow transplantation: value of Gray-scale and Doppler US in 100 patients. Radiology 1997; 204: 545–52.CrossRefGoogle Scholar
62: Mowat, AP. Biliary disorders in childhood. Semin. Liver Dis. 1982; 2: 271–81.Google Scholar
63: Fried, MW, Connaghan, DG, Sharma, S, Martin, LG, Devine, S, Holland, K et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24: 588–91.CrossRefGoogle ScholarPubMed
64: Norris, S, Crosbie, O, McEntee, G, Traynor, O, Molan, N, McCann, S et al. Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation. Ransplantation 1997; 63: 1521–4.Google Scholar
65: Huxtable, RJ. The myth of beneficient nature: the risks of herbal preparations. Ann. Int. Med. 1992; 117: 165–6.Google Scholar